uniQure chief legal officer sells shares for $72,812

AMSTERDAM—uniQure N.V. (NASDAQ:QURE) Chief Legal Officer Jeannette Potts recently sold 7,076 ordinary shares in a transaction valued at approximately $72,812. The sale, executed on March 4, was conducted at a weighted average price of $10.29 per share. The transaction comes as QURE’s stock has shown significant momentum, posting a 105% gain over the past six months despite recent volatility. InvestingPro data reveals the stock currently trades at $12.09, with 11 additional key insights available to subscribers. According to the filing, the shares were sold to cover estimated withholding taxes upon the vesting of restricted share units, as stipulated in the relevant Restricted Share Unit Agreement.

In addition to the sale, Potts acquired 35,000 restricted share units on March 3, which were granted under uniQure’s 2014 Share Incentive Plan. These restricted share units vest in equal annual installments over three years, contingent on Potts’ continued relationship with the company.

Furthermore, Potts was granted stock options on March 3, allowing her to purchase 60,000 ordinary shares at an exercise price of $10.90. These options will vest over a period, with 25% vesting on the first anniversary of the grant date and the remainder vesting quarterly thereafter, subject to her continued employment with uniQure.

Following these transactions, Potts holds a total of 119,743 ordinary shares directly.

In other recent news, uniQure has announced the pricing of its public offering of 4,411,764 ordinary shares at $17.00 each, aiming to raise approximately $75 million in gross proceeds. This offering is expected to close around January 10, 2025, pending customary conditions. H.C. Wainwright has reaffirmed its Buy rating for uniQure, maintaining a $70 price target, citing optimism about the company’s progress in gene therapy, particularly for Huntington’s disease. The firm highlighted the significance of upcoming milestones, including a potential Biologics License Application filing for the AMT-130 program.

In addition, uniQure has completed enrollment for the first cohort in a Phase I/IIa trial of AMT-191, a gene therapy for Fabry disease, with no significant safety concerns reported. The company plans to proceed with dosing the second cohort. Meanwhile, CSL (OTC:CSLLY) Behring, which partnered with uniQure for the development of HEMGENIX, confirmed the long-term efficacy of this hemophilia B treatment, showing sustained factor IX activity levels and a significant reduction in annualized bleeding rates over four years.

uniQure continues to advance its gene therapy pipeline, which also includes treatments for refractory mesial temporal lobe epilepsy and SOD1-ALS. The company’s strategic developments and clinical advancements are being closely monitored by investors and analysts alike.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.